Komori
Eiken Chemical (4549) · TargetAdvanced

Simple, rapid infectious disease diagnostic systems that anyone can use anywhere

First written in FY2022. 5 of 6 entries say "Advanced", first in FY2023. Latest entry: 2026-07-30.

6entries
5years
2from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseFirst statedFY2022AdvancedFY2023 – 2026-07-302022: 120222023: 120232024: 120242025: 120252026: 22026
Same theme, other companies
Simple, rapid infectious disease diagnostic systems that anyone can use anywhereA theme 1 companies write about · 0 as a headwind · 1 as a tailwind

No other company in this theme has enough history to compare yet.

Full recordFilings, disclosures and news, newest first
  1. FY2025AdvancedAnnual report

    「For urine test strips, we launched the compact, portable “US-1300” automated urine analyzer, the successor to US-1200, as the compact model in the US series in November 2024. In December 2024, we launched the fully automated “US-3600” urine analyzer, the successor to US-3500, as the flagship model in the US series.」

    In connection with the goal of developing simple, rapid and accessible testing systems, the company launched new products such as the portable US-1300.
  2. FY2025-H1AdvancedAnnual report

    「Sales of new rapid diagnostic kits, “ImmunoCatch–StrepA” and “ImmunoCatch–Adeno,” increased, bringing microbiological testing reagents to ¥2,194 million, up 3.0% year on year.」

    In connection with the goal of developing simple and rapid infectious disease diagnostic systems, sales of 2 new rapid diagnostic kits increased.
  3. FY2023AdvancedAnnual report

    「We will contribute to improving access to healthcare by developing simple, rapid and accurate infectious disease diagnostic systems that anyone can use anywhere. In addition, as a response to COVID-19, we launched the “Exdia EK Test” series of highly sensitive immunochromatographic systems capable of testing for antigens of SARS-CoV-2 and influenza A/B from a single swab specimen.」

    In connection with the goal of developing simple and rapid infectious disease diagnostic systems, the company cited the launch of a product that tests for SARS-CoV-2 and influenza A/B using a single swab specimen.
  4. FY2022First statedAnnual report

    「We will contribute to improving access to healthcare by developing simple, rapid and accurate infectious disease diagnostic systems that anyone can use anywhere.」

    The company stated for the first time a policy of developing simple, rapid and accurate infectious disease diagnostic systems that can be used anywhere.
Moved together

"Development of Global Products and Commercialization of New Products" moved the same way as this thread, in the same document, in 5 of its 6 moves.

543322★123456
  1. ★This thread
  2. 1Development of Global Products and Commercialization of New Products5×
  3. 2Strengthening the Financial Position by Reducing Total Assets and Improving Capital Efficiency4×
  4. 3Development of testing systems for cancer treatment selection and assessment of treatment efficacy3×
  5. 4Developing and Leveraging Talent, and Developing Global Talent3×
  6. 5Accelerating Global Expansion2×
  7. 6Market Expansion of Fecal Occult Blood and Urine Testing Products in Overseas Markets2×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
Eiken Chemical's next results are scheduled for 2026-10-29. Read the earnings preview It last moved in the Business Alliances of 2026-07-30: "Advanced".
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Simple, rapid infectious disease diagnostic systems that anyone can use anywhere | EIKEN CHEMICAL CO.,LTD. (4549) | Komori